Firstly, not all of the conversion of Ang I to Ang II occurs through ACE since this can also occur via chymase and some other recently-described enzymes (e.g. cathepsins). Perhaps this is more important within tissues but it is an ACE-I-insensitive route by which this conversion can occur. However, ACE-I do other things: they prevent ACE degrading a number of peptides and perhaps the most important one here is bradykinin, which is metabolised normally by ACE into inactive fragments. Inhibition of this process therefore elevates bradykinin levels, exaggerating effects mediated by B 1 and B 2 receptors. Clearly these are effects that would not be shared by an ARB.
Ang II undergoes further metabolism into Ang III (or Ang 2-8) and subsequently Ang IV (Ang 3-8) through progressive loss of amino acids 1 and 2 from the Ang II molecule. Ang III can act on both the AT 1 -and AT 2 -receptor, as does Ang II. More recently another angiotensin receptor, the AT 4 -receptor, has been described, which may be activated by Ang III and Ang IV and again this is another potential focus of action of the renin-angiotensin system that will not be directly affected by selective ARBs.
Finally, another parallel pathway not involving ACE but a related enzyme ACE-2 has been described relatively recently. ACE-2 converts Ang I into Ang 1-9 or Ang II into Ang 1-7. Ang 1-7 has its own receptor which seems to be a protein related to the product of the mas oncogene. Ang 1-7 has a number of actions which I will describe later, but it represents another element of this ever-increasingly complex pathway that could in theory account for differences between ACE inhibition and AT 1 -blockade.
Finally, Ang 1-7 can be broken down into Ang 1-5 and as far as I am aware there are no assigned roles for this peptide.
Introduction
At the September 2005 meeting of the British Hypertension Society a mini-symposium was held on the theme of "ACE inhibitors and angiotensin receptor blockers: similarities and differences". The talks and the subsequent discussions were recorded and transcripts prepared, which were later edited, revised and up-dated by the authors. This is now presented here and provides the considered analyses of large bodies of data. In this format, as at the meeting, the presentations reflect the speakers' individual styles. this receptor is present in foetal tissue but is also seen in other sites in adult tissues such as the adrenals, ovaries and in vascular endothelium. 6 There is increasing evidence that this receptor may play an important role in regulating growth in the vasculature and vasodilation at least in some beds.
Mas receptor for AT 1-7: this has been reported to be present in kidney and heart and seems to be involved in blood flow and renal sodium handling 2 AT 4 -receptor: This is present in the brain and in vascular tissues, and again may be involved in blood flow, renal sodium handling and memory. 7 Coming to some of these elements in a little more detail, the AT receptor seems to act predominantly as a functional antagonist of the AT 1 -receptor, at least in most settings. 8 It mediates vasodilation in some blood vessels, such as the coronary artery, and this effect seems to be mediated, at least in part, through increased bradykinin levels, stimulation of endothelial nitric oxide production and cyclic GMP. In the kidney the AT 2 -receptor, at least in the rat, inhibits renin release, probably by direct action on the juxtaglomerular apparatus.
There is also evidence that it can exert inhibitory effects on growth of cardiac myocytes and may inhibit perivascular fibrosis in the heart. 2 ACE-2 is a relatively recently described enzyme that now forms part of the renin-angiotensin system (Hooper NM, Turner AJ. Nature Structural Biology 2003; 10:155-157) . It is a carboxypeptidase with some degree of similarity to ACE but is not inhibited by classical ACE inhibitors. It converts Ang II to Ang 1-7 and also metabolises a variety of other peptides such as neurotensin and dimorphin, but it does not possess the capacity to break down bradykinin. It is expressed in the heart, kidney, endothelium, smooth muscle, and the expression of the enzyme appears to be upregulated, at least in some animal models of hypertension. 9, 10 Interestingly, it has also been reported to act as a receptor for severe acute respiratory syndrome (SARS) corona virus 11 and may play some role in that disease though this is controversial.
Ang 1-7, the major product of ACE-2 can act as a functional antagonist of AT 1 -receptors in some circumstances. 9, 10 It is now believed that the effects of this peptide are mediated by activation of the mas receptor. Ang 1-7 causes vasodilatation in some beds, again seemingly involving bradykinin, and can inhibit smooth muscle growth in vitro. In the kidney it can induce a diuresis or natriuresis and this appears to involve a tubular action.
To try to summarise and draw out the differences now, rather than the similarities. I have depicted the effects of ACE-I and ARBs on the key components of the renin-angiotensin system (Figure 2 ). You will see that ACE-Is reduce the levels of Ang II, so therefore one would expect them to reduce signalling through the AT 1 -receptor and the AT 2 -
Figure 1
The renin-angiotensin system and its effectors.
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Ang ( In contrast, ARBs, although they will block effects on AT 1 -receptors, are likely to increase signalling through AT 2 -receptors because they elevated levels of Ang II. A similar argument applies for Ang III and Ang IV, although in the case of Ang IV the effects of elevating levels of Ang IV by ARBs are likely to be mediated through increased signalling via the AT 4 -receptor.
Finally, ACE inhibitors increase bradykinin, but there is some evidence that ARBs may also increase bradykinin via enhanced signalling through the AT 2 -receptor. 12 The elevation in bradykinin due to ARBs may be less marked than with ACE-I and this may account for considerably less frequent incidence of cough. 4 Moving on to the other aspects of these drugs -and these are effects not mediated through actions on the renin-angiotensin system at allthere are data showing that ACE-I binding to the ACE enzyme can induce intracellular signalling. 13 Binding of the ACE-I causes phosphorylation of the cytoplasmic tail of ACE through casein kinase and that this can result in JNK activation and increased cyclooxygenase type 2 (COX-2) activity. It has been suggested that this may result in increased prostacyclin levels and may account for some vasodilatory actions that have been described in vitro with ACE inhibitors in the absence of activation of renin-angiotensin system.
There are a number of non-renin-angiotensin system actions of ARBs that have been described. 5 A number of these are restricted to specific members of the class. Several ARBs, including losartan, EXP3174, (the active metabolite of losartan), irbesartan, valsartan and eprosartan have been reported to act as thromboxane (TXA 2 ) antagonists. It remains unclear how clinically relevant these are but they have certainly been clearly described in vitro. Losartan and its metabolite, EXP3174 can also act as tachykinin receptor antagonists and losartan may have uricosuric effects in the kidney via inhibition of the urate-lactate and urate-chlorate exchanger. At least two ARBs, telmisartan and irbesartan, seem to have some ability to stimulate the peroxisome proliferatoractivated receptor-gamma (PPAR-g), 14, 15 and it has been suggested that this might contribute to the beneficial effects of ARBs on glucose tolerance in some individuals.
To summarise, ACE inhibitors and ARBs share the ability to inhibit AT 1 -mediated effects in vivo. However, ACE inhibitors and ARBs differ in effects on less well understood components of the renin-angiotensin system and some of these agents possess actions that are unrelated to their effects on the renin-angiotensin system. As yet, I would say that the clinical significance of these differences remains to be established. Thank you. Hughes: Tough question! Since I have a persistent cough already I would probably go for an ARB because of the reduced incidence of cough.
Questions from the Floor

Chair: Nothing from the scientific point of view?
Hughes: I do not personally believe that as yet there is good enough basic science evidence to stick my neck out and say there are going to be any other clinically significant differences.
Sever:
Can you say anything about the brain penetration of these two classes of compounds and to what extent differences may be related to inhibition of the brain's renin-angiotensin system?
Hughes:
That is an interesting question. There is still not that much data. Thomas Unger's group has done a lot of work which focuses particularly on the ARB, telmisartan suggesting an effect via AT 2receptors. 16 There is also quite a lot of interest, as I mentioned, in some of the non-classical elements -AT 4 -receptors perhaps particularly -in brain function. These effects may relate to memory. There are certainly studies in animals that suggest that inhibition of that pathway within the brain can affect memory-related performance. 7
Sever: I was interested in the experimental data suggesting some degree of neur oprotection with ARBs which clearly are independent of blood pressure-lowering, and in various models of hemiparetic stroke the degree of neurological deficit appears to be inhibited by ARBs but perhaps not by ACE Hughes: Those are interesting observations. They are independent of blood pressure but whether they are independent of vascular effects remains to be ascertained.
Question (Simon):
You have summarised a lot of information very succinctly. What mechanism is there to explain ARB-related cough?
Hughes: I am not sure we fully understand ACE inhibitor-related cough, but the suggestion is that the ability of ARBs to elevate levels of bradykinin and possibly related tachykinins through the AT 2receptor may be responsible for that.
Hingorani:
Have there been any studies done in humans that have indicated that there are truly differences in circulating angiotensin peptide profiles among individuals who have been given either ARBs or ACE inhibitors, or was the slide that you showed what you might expect in theory?
Hughes: I am aware of one study by Campbell and others which looked at levels of angiotensin peptides and ACE-I. 16 They did not find that ACE-I had much effect on circulating levels of Ang 1-7. You may want to make an argument that circulating peptides may not reflect tissue peptides, but there is a limited amount of in vivo data as yet.
Chair: If there are no more questions we will move on. Thank you, Alun. The next way of looking at this question is the renal/diabetic view and Bryan Williams will give it to us. Williams: Thank you, Alun, for setting the scene for this with that excellent review of the renin-angiotensin system. I thought I would begin with just a few points. I have been given a subject to address for which there is little or no data! When comparing ACE-I or ARBs for renal protection and/or in patients with diabetes, there are inadequate data on hard clinical endpoints. This is an important issue because as most of the different classes of blood pressure-lowering drugs become generic, then clearly the 'A' group (ACEs and ARBs) are going to be an area of increasing focus.
In terms of renal outcomes, particularly in diabetes -and most of the studies in diabetes in which these two drug classes have been based on renal outcomes, a change in albuminuria or change in GFR has been used as the endpoint to try to indicate benefits from these treatments.
Most of the data is in Type 2 diabetes.
Why might there be differences in outcome with these different methods of blocking the RAAS? Alun has already covered this, but I thought
In terms of nephro-protection, then, when compared to alternative BP-lowering drugs, there appears to be an advantage in people with advanced nephropathy of blocking the renin system with either of these drugs classes.
What about head-to-head studies comparing ACE-I with ARBs? This is where it starts to go downhill because we do not have a lot of data to discuss in this context. A meta-analysis was published in the BMJ recently which attempted to see whether there were differential effects of ACE-I or ARBs on mortality and renal outcomes in people with diabetic nephropathy. The analysis of mortality is awful in the way it has been done and interpreted, so I am going to focus on the renal outcomes in this review.
The objective here was to evaluate the effects of ACE and ARBs on renal outcomes or death in patients with nephropathy. One of the problems with these kinds of analyses, particularly when looking at all-cause mortality, is that you end up with an amalgam of vastly different studies -some of which purely focus on renal outcomes and were designed to do that -these are mostly studies with ARBs. Then you have a whole range of ACE inhibitor studies in which there were surrogate endpoints and secondary endpoints of renal progression, but the primary outcomes were mainly cardiovascular, so -not surprisingly -with the ACE inhibitor studies, there was more power to look at cardiovascular outcomes in completely different patients to the ARB studies, which is why this is a terribly unbalanced way of looking at mortality. However, they do provide some data in relation to the theme of this talk, that is nephropathy.
Herein lies the problem. Thirty-six of 43 identified trials compared ACE inhibitors with placebo. That does not really help us at all because what they are going to try to do is extrapolate across to comparisons between two different sets of placebo-controlled trials, one with ACE and one with ARBs, and that, quite frankly, is hopeless unless the trials are well matched -and often they are not. Only four studies compared ARBs with placebo, and three compared ACE inhibitors with ARBs but look at the numbers here -206 patients. This analysis actually misses one important paper which I am also going to show you later. They also obtained some unpublished data from 11 trials.
ACE inhibitors against placebo or no treatment.
Looking at doubling of serum creatinine as a marker of progression of renal disease, you can see that there is about a 40% reduction in relative risk -in favour of ACE inhibitors. If you look at end stage renal disease -and I caution you here, the numbers in some of these studies -9, 13, 16, 9 -we are dealing with tiny studies. All the power is in one or two studies, one of which was not really designed to look at this question. We it would be interesting to summarise it from a clinical perspective. There are differences between these two classes of treatment. Somebody asked about hormonal profiles. Renin tends to be much higher on an ARB, and as we begin to see the emergence of renin inhibitors etc. this is going to be interesting. Angiotensin II levels are generally higher with ARBs and obviously reduced by ACE inhibition. There has been speculation about the role of the angiotensin AT 1 -and AT 2 -receptors, the balance of activation of these receptors being different, depending on whether the RAAS system is interrupted by an ACE-I or an ARB. Then the data surrounding bradykinin and cough, also point to differences.
If you look at animal models -the SHR, the partially nephrectomised rat, the streptozotosin diabetes rat -if you look at the data from all of these experimental models, the ACE inhibitors and the ARBs appear to have similar actions in terms of reno-protection and for various surrogate markers of cardiovascular disease.
One interesting difference in relation to the kidney was highlighted by this very elegant study, which I have tried to illustrate in a cartoon form by bringing together a lot of data from a single paper from Norman Hollenberg's group at Harvard. In patients, they have used increases in renal plasma flow as an index of the degree of inhibition of the renin-angiotensin system, and nephrologists will see this as a reasonable surrogate for blockade of the renin system. ACE inhibition resulted in a big increase in renal plasma flow.
They then looked at the effects of renin inhibition. Of course, at this time this was only intravenous renin inhibition, and you see a bigger increase in renal plasma flow with direct renin inhibition, suggesting that ACE inhibition is not giving as complete blockade of the RAAS as renin inhibition. When they looked at ARBs, they saw an increase in renal plasma flow which was about equivalent to that seen with renin inhibition and clearly greater than that seen with ACE-I. So this elegant study provides some evidence in patients that there may be effects on renal haemodynamics which are different between these two drug classes.
If we look at what we know in terms of renal outcomes in people with diabetes. Firstly, ACE inhibitors -and this is really captopril against placebo in the famous Lewis study published in 1993 in the New England Journal -delay the progression of advanced nephropathy in people with Type 1 diabetes. All other data in this regard is in Type 2 diabetes. In IDNT which compared an ARB (irbesartan) against placebo or amlodipine-based treatment, the ARB delayed the progression of nephropathy more effectively than the comparators. Similar results were seen in the RENAAL study which compared losartan against conventional therapy plus placebo and the ARB delayed the progression of nephropathy more can again see around a 36% reduction, suggesting that treating with the drugs that block the renin system -in this case, ACE inhibition -is better than no treatment at all in terms of protecting against progressive renal disease in people with established renal disease.
Next, the data with ARBs. The first thing to say is that the studies are bigger in many cases, but there are fewer of them. ARBs against placebo or no treatment -looking again at doubling of creatinine or at progressive end-stage renal disease, you see a benefit in favour of the ARBbased treatment of around 30% reduction in progression to end-stage renal disease. So, on balance, you are looking at an equivalent effect to that seen with ACE-inhibition, and that is about all you can say for it.
If we look at another surrogate of renal disease progression which is much loved by the diabetologists and the nephrologists -notably the progression from microalbuminuria to macroalbuminuria -again the numbers are tiny in many of these studies. Looking at ACE inhibitors against placebo or no treatment -there is a clear benefit of using active treatment in people with microalbuminuria, stopping them progressing to macroalbuminuria. Of course, much of this could be related to blood pressure differences because that is a powerful determinant of albumen excretion.
Now comparing ARBs against placebo or no treatment -again, very small numbers in some of these studies. But there is certainly a strong suggestion that this will delay the progression of nephropathy from microalbuminuria to overt proteinuria. But I emphasise, these are not headto-head trials comparing ACE-Is with ARBs; they do not directly answer the question posed by the title of this talk. However, they suggest that both classes of drug are having similar effects on both surrogate renal endpoints and hard renal endpoints.
One interesting thing that comes out from this meta-analysis is that if you look at the side effects of these drugs -and it is my own personal view that this will be the issue ultimately that probably differentiates these two classes from a purely clinical perspective -cough was the side effect that came out as being significantly different, but there is really not much else in this analysis.
Towards the end of 2004 in the New England
Journal Tony Barnett and his group from Birmingham, on behalf of other investigators around Europe, published a study looking at angiotensin receptor blockade versus converting enzyme inhibition in patients with Type 2 diabetes and nephropathy. It is the first head-tohead study that directly asks the question in this talk. The primary endpoint here is looking at the progression of GFR, so a surrogate endpoint in Type 2 diabetic nephropathy. These people have Type 2 diabetes -~250 of them -randomised, to either treatment with enalapril 20 mg/o.d. or telmisartan 80 mg/o.d. Eighty per cent of them had microalbuminuria and 20% overt proteinuria or albuminuria and therefore more advanced disease -mean age 61 years. Other drugs could be added after randomisation to get their blood pressure down below 130/80. The primary endpoint was change in GFR over five years, measured with isohexol, which is probably the gold standard way of doing this in this kind of trial. It is good to see a really good analysis of a change in GFR rather than simply plotting reciprocal of creatinine.
The GFR actually fell in both groups, as it will in patients with diabetic nephropathy and there is absolutely no difference in the rate of decline of GFR between the two groups. The study was also powered to show non-inferiority of telmisartan, and that is what they concluded, that basically telmisartan looked to be as good as enalapril in delaying the loss of GFR in patients with established nephropathy. There were no major differences in blood pressure, which I would argue is why there was no difference between the drugs! In terms of ACE versus ARBs, that is about it on renal progression data. Another thing that I should comment upon is the excitement generated in nephrology meetings about the possibility of adding ACE-I and ARBs together. This is before we have any evidence that either alone is necessarily better than the other! There have been some poorly designed studies looking at this, but I will show you the first one that looked at this and it generated a huge amount of interest.
This was done by Mogenson and Cooper -very good investigators. Their patients took candesartan 60 mg/o.d. or lisinopril 20 mg/o.d. or the combination. There were similar blood pressures at baseline, and they had a similar baseline albumen-creatinine ratio in their urine. This study is known as the CALM study. Blood pressures fell to about the same degree on candesartan or lisinopril monotherapy. The blood pressures fell a lot more with the combination, which suggests to me something that neither of these drugs is optimal in its dosage and that the combination is simply providing a more effective and complete inhibition of this system. To do these kinds of studies properly we need more than one dose of each of these agents and we need to study them at very high doses to see whether you can go beyond the effects of maximal or supramaximal doses of each these drugs by combining two treatments. Nevertheless, there was a bigger reduction in albuminuria with the combination, but again it is difficult to interpret the mechanism if you have substantially lower blood pressures with the combination because blood pressure is a hugely powerful determinant of albumen
There are studies now ongoing looking at various surrogates such as changes in BNP, changes in albuminuria and indeed studies in heart failure looking at hard outcomes with high doses of ACE-I or ARBs and the combinations.
The one study that will probably be the first one to report its outcome where there is a direct head-to-head comparison of ACE-I and ARBs is the On-Target study, which has over 20,000 patients randomised to three arms -1) telmisartan, 2) ramipril and 3) the combination of the two drugs. About a quarter of the patients had diabetes at baseline, some of whom will have some degree of renal impairment which will progress, so this should give the study sufficient power to look to see whether either of these drugs, or the combination is superior in terms of cardiovascular outcomes and potentially some renal outcomes and also outcomes in people with diabetes.
Finally, although we look for differences between drugs based on their biological actions, much of which is speculative, there might be a simple reason why ARBs may turn out to be superior to ACE-I, notably the longer duration of action of ARBs and thus their potential to deliver better 24-hour blood pressure control. In our unit we have been involved in a a large ambulatory BP study comparing telmisartan and ramipril, in doses similar to those used in On-Target. The study recruited about 800 patients and is termed PRISMA-I. Telmisartan (80 mg) provides superior 24-hour BP control as compared to ramipril (10 mg) and the differences between the drugs are most notable in the last few hours, that is the early morning hours, when most cardiovascular events occur. If the On Target study turns out to show a difference between these two classes of drugs -I am sure everybody will then speculate that it relates to the mechanisms alluded to by Alun in his review -the reality is that it might simply relate to differences in blood pressure load over 24 hours and it is likely that blood pressure control will have been better over 24 hours with the ARB rather than with the ACE inhibitor. I do not believe that this has been talked about enough as a potentially significant difference between these classes of drugs, particularly when used in monotherapy.
My conclusion is that both of these classes of drugs in people with diabetes are effective at retarding the progression of albuminuria as a surrogate for renal disease progression and retarding the decline in renal function, but there are inadequate 'head-to-head' studies. We also have inadequate data regarding direct 'head-tohead' comparisons for hard clinical endpoints in patients with diabetes and/or renal disease.
In other disease areas that we shall hear about, such as heart failure, post-MI etc., have suggested broadly similar outcomes when ACEs and ARB have been compared 'head-to-head', suggesting that the same may be true when looking at renal outcomes in well-conducted studies in future. Ongoing studies will help clarify this issue to some extent although I dare say there will continue to be a debate. Thank you. Williams: Perhaps. The difference between that data and the data I showed from the pure ambulatory study that we have done comparing the two agents is primarily due to the fact that our study was a monotherapy study and in many of the patients in Tony Barnett's study the telmisartan and the enalapril was added into other drugs, so to some extent that will potentially mask any difference in blood pressure, once you have combinations. Also, they have looked at the progression of GFR. The error on that is quite wide, as nephrologists will tell you. It probably only just had sufficient statistical power to look at any potential differences between those two agents. Two-hundred and fifty patients? Not a lot when you have so many variables. So there was limited power -it was probably underpowered to address the question adequately.
Questions from the Floor
Chair: What about the renal doc's propensity to look at microalbuminuria as the meaning of life? As a surrogate, how solid is it? Clearly it is all right for renal function but in terms of cardiovascular disease how much attention should we be paying?
Williams: In renal function terms, there is no doubt that there is a good correlation between albumin excretion rate and progression of renal disease, certainly in diabetes. The problem comes from the fact that you have a very strong correlation between albumen excretion rates, and cardiovascular outcomes in Type 2 diabetes. In other words, if you have a high albumen excretion rate you are more likely to die prematurely of cardiovascular disease than you are of renal disease if you are a Type 2 diabetic.
If albuminuria was the perfect surrogate for cardiovascular protection, you would expect the drugs that reduce albuminuria more effectively to be more effective at reducing cardiovascular outcomes in diabetes. Actually, although this has never been properly studied. If you take, for example, ALLHAT or many other studies where you have a CCB against an ACE or an ARB, you would
definitely have ended up with a differential effect on albuminuria between the two treatment arms in patients with diabetes, we did not necessarily see a differential effect on cardiovascular outcome. So the evidence does not necessarily support a direct translation between the ability to reduce proteinuria and the ability to reduce cardiovascular risk. One thing I would add is that there was a very good analysis done by Dick de Zeeuw of the RENAAL data in which he plotted the change in albumen excretion after six months of initiation of either the ARB or the placebo in that trial and then looked at the renal outcome and the cardiovascular outcome in those populations. He saw a relationship: those patients who had more than 30% reduction in albuminuria in their first six months of treatment, ended up having a better cardiovascular and renal outcome at the end of the trial.
It is very much a post hoc thing.
Chair: Combining both drugs?
Williams: No, comparing losartan with a placebobased treatment. We do not have anything on the combination.
Chair: I suppose the key question, then, is from a diabetic kidney point of view, which would you take for you? And you are not allowed to say 'cough' as a determining factor.
Willlams: It is always difficult to say what you would do personally because it is not necessarily the same thing as you would do in clinical practice! That is a difficulty that we have. If you make a decision on the evidence, the evidence in Type 2 diabetes is strongest for the ARBs because they have been the most recently studied drugs and in Type 2 diabetes they have been the best studied. One of the things you can get from these studies is some impression of what the optimal dose was to achieve that benefit in that study. I personally would take an angiotensin receptor blocker in combination with a CCB, but probably more because of the lack of side effects than any other evidence that I am convinced about. I do not think we should always diminish the side effect issue in relation to drugs; it is potentially quite important. If you were to talk to doctors who take either ACE or ARB you will almost invariably find that the decision they have made is not on the basis of hard endpoint data; it is often on the basis of the side effect profile.
Cruickshank:
We are on a running train for the lower the better for diabetes anyway as far as the pressure is concerned. Probably a lot of people are ending up on both ARBs and ACEs. The question I wanted to ask was whether you believe either or both agents blunt the GFR rise that you get with the dihydropyridines that some nephrologists regard as a reason for not using dihydropyridines in renally compromised people.
Williams: That was a big debate at one time when people were trying to decide whether to use ACE or ARBs or dihydropyridines as the primary means of lowering pressure. But as you know, Kennedy, nowadays, for right or wrong, there is a general view that all diabetics should be on some form of renin-angiotensin system blockade. That view is more strongly supported if they have renal disease than anything else, so they are going to be on renin-angiotensin system blockade anyway. If you go back to RENAAL, 60% or more of the patients were actually on a dihydropyridine in that study; it was amlodipine for most of them. If you look at the outcomes of those patients compared with other studies that have used different types of add-on drugs in comparable populations there is no evidence that the addition of a dihydropyridine in any way negates or blunts the benefit associated with renin-angiotensin system blockade.
There is plenty of good evidence that CCBs in combination with ARBs or ACEs and diuretics are incredibly effective at lowering pressure in Type 2 diabetes and very effective at reducing adverse outcomes in the cardiovascular system. So my own view would be that CCBs are an essential component of treatment: you cannot really control blood pressure without them and the debate is really about the optimal combination for these patients. The priority should be to get their pressure down, as you are well aware. When GPs ask me about whether combining ACE and ARBs is something they should be doing, I always say that there are better things to combine with ACE or ARBs in people with diabetes, and that is a diuretic or a CCB, because you will get more blood pressure-lowering. At the moment that looks overwhelmingly more important than racking up the renin blockade to doses that we do not know enough about in terms of outcomes.
Chair: Kennedy, your throwaway comment that most of these patients are getting both ACE and ARBs in diabetes -is that real?
Cruickshank: I am talking about people trying to get blood pressure control. You know in ASCOT that we aimed for 130/80 in diabetes and did not get there. What do you do? You keep racking up and you combine with other things, and you do get some extra blood pressure difference. Whether you get anything else with the two combined.
Williams:
The one area where you do see the combination of ACE-I and ARBs being used more commonly -and it is purely empirical although there is some limited evidence -is in patients with heavy proteinuria. In patients with nephrotic range proteinuria, either due to diabetes, membranous nephropathy or focal sclerosis or something else, where it is actually very difficult to control the amount of protein in the urine, nephrologists have been using very high doses of ACE inhibition and very high doses of ARBs, often in combination, and in some patients that can be quite impressive at reducing the loss of protein in the urine. But that is again treating a surrogate, not necessarily generalisable to the population who have lower levels of proteinuria where blood pressure-lowering is probably going to be just as impressive on top of renin blockade at reducing their albumen excretion.
Question: I have a question which is ACE versus
ARBs versus other blood pressure-lowering drugs. As you showed, most of the studies in this area have been placebo-controlled and there will have been inevitable blood pressure differences. I do not think there are many studies of these drugs versus other active components or the older antihypertensive so how much of this do you think is really an effect on the renin-angiotensin system and how much is simply blood pressure-lowering?
Williams: There is little doubt, both from animal physiology, human physiology, data in measuring albumen excretion in patients, that if you regard albuminuria as a surrogate for pressure differences in the kidney, there is a benefit or an effect of blocking the renin system to reduce albuminuria which occurs on top of the expected reduction in albumen excretion due to blood pressurelowering in patients with proteinuria. I guess the best demonstration of that came from IRMA II where irbesartan was compared head-to-head directly with amlodipine, and despite identical brachial blood pressures in that study there was a differential in the reduction in albuminuria.
Whether that matters in the long run to outcomes is another issue. There is definitely something about blocking the renin system that reduces albumen excretion in patients; I do not think there is any doubt about that.
However, the broader issue about how that translates into hard cardiovascular outcomes is still debatable. It has not necessarily faithfully transformed the outcomes of patients with their systems blocked in diabetes, because we have had very good outcomes in diabetic patients treated with alternatives. I draw your attention to the latest blood pressure trial meta-analysis by the BPLTTC published recently in Annals, which just looked at the diabetic cohorts in trials. Its conclusion was that the primary benefit of lowering blood pressure in diabetes is achieved by the blood pressure-lowering and not necessarily the drugs used to achieve it, although many people would have renin-angiotensin system blockade as part of their combination because of the effects on the kidney.
Chair: So the BHS guidance to compelling indication for Type 2 diabetes remains as ARBs as the first line rather than ACE?
Williams: The way it has been written was largely because we generally stuck to where we had the strongest evidence. For example, we did not have as much evidence in Type 2 diabetic nephropathy with ACE inhibitors as we have with ARBs. One of the options we have in the future is to try to analyse this data in a different way and ask the question as to whether there is enough evidence to suggest there is likely to be a difference based on what we know from studies such as those we have discussed today -that is another way of looking at it -rather than just sticking with the hard evidence. At the moment we have tended not to be judgemental and present what the evidence says.
Heart Disease Dr Adrian JB Brady
Consultant Cardiologist, Department of Medical Cardiology, Glasgow Royal Infirmary.
It's a great honour to be asked to give this talk. I have looked at this subject in four clinical groups: patients with stable coronary heart disease; atrial fibrillation; patients who have had myocardial infarction; and patients who have heart failure.
For patients with stable coronary heart disease there is a great deal of evidence for ACE inhibitors and very little for ARBs. We all know the EUROPA trial, 1 a large study, published over a year ago -patients with established, stable coronary heart disease without heart failure. They were randomised to perindopril at 8 mg or placebo and they are then followed up over five and a half years. The primary endpoint was reached. You can see that there was a 20% relative risk reduction in the combined endpoint of cardiovascular death, non-fatal MI and cardiac arrest (Figure 1 ). That was highly significant.
Fatal and non-fatal myocardial infarction -also about a quarter fewer events with perindopril versus placebo. Heart failure, as you would expect -quite a big difference in new heart failure cases with perindopril during the course of the trial.
This has been quite big news in cardiology. The FDA and the EMEA have taken this on board in terms of licensing of perindopril for cardiovascular protection for patients with established coronary heart disease. Of course, there is more than one trial and these are the four major trials of patients who have stable coronary heart disease without heart failure, who are then randomised to ACE inhibitor or placebo. In HOPE ramipril worked. EUROPA worked. Trandolapril in PEACE had no significant benefits. There were slight differences in the patients. PEACE was a more recent trial with greater use of statins and greater use of revascularisation. But the evidence from these four studies is that the benefits are not necessarily the same for every ACE inhibitor. Quinapril in the QUIET study -this was a group of patients (about 1,500) who had had cardio-pulmonary bypass -they went on to ACE inhibitors, so it was rather a small study.
People often say that all ACE inhibitors are the same. This is the best slide to say that they are not necessarily the same (Figure 2 ).
In this patient group there are really no largescale ARB studies to present, so for this section of patients with stable coronary heart disease and not heart failure the ACEs have it.
Atrial Fibrillation
What about atrial fibrillation? That is emerging as a big growth area in cardiology and in cardiovascular medicine as a whole. There is some quite exciting data. This is Kennedy's excellent survey in the northwest of England showing the combination of risks. 2 If you have hypertension and you have atrial fibrillation you can see there is a ten-fold risk of stroke. Atrial fibrillation is by far the biggest risk factor for stroke once you have hypertension. Stroke patients are older and have other additional co-morbidity, but AF is far and away the most important risk factor.
The best data comes from the LIFE trial. 3 This is the sub-study which has just been published. There were about 9,000 patients in the overall LIFE trial: 8,851 had hypertension with LVH and no atrial fibrillation at the outset. They were assigned to losartan or atenolol and followed up. They had ECGs done every year. Figure 3 shows the events in people who developed atrial fibrillation during the course of the LIFE trial.
If you develop AF the event rate is very substantially increased compared with people who did not develop AF during the trial. It is a good presentation of the importance for people who develop atrial fibrillation during the course of the trial -very high numbers of endpoints compared with patients who remained in sinus rhythm, whether it is stroke, composite endpoint or whatever. The point was that patients who received losartan had a reduced incidence. You can see that 7-8% of the atenolol group developed AF during the course of the trial. We all used to use beta-blockers in the belief that they control to some extent and may even reduce the onset of atrial fibrillation, and by the trial design the patients who received losartan did not receive a beta-blocker. So they were denied the electrophysiological benefits of a beta-blocker in that limb of the trial, yet had far less atrial fibrillation. That is a very exciting finding. An ARB plus a betablocker is probably the best combination to prevent atrial fibrillation in somebody who was prone to it -say somebody with valvular heart disease.
LIFE, unlike all the other hypertension trials, had a reasonable number of patients with atrial fibrillation at outset. This was either paroxysmal Again they were randomised to losartan As you know, if you have paroxysmal AF your stroke risk is the same as somebody who has sustained, persistent atrial fibrillation, so we should accept those things as being identical in terms of risk of stroke.
This is new data published recently in JACC.
It looks at the primary composite endpoints (Figure 4 ).
You remember the composite endpoint included cardiovascular death, non-fatal MI and stroke. There is a very big difference again -look at the incidence of events in the atenolol group -40% had events. Again, a huge number of events if you have atrial fibrillation during the course of those five years of the trial. That is reduced by about 42% with losartan. The losartan patients were again denied beta-blockers by the trial design. Look at the risk of stroke -reduced by 45%so here too huge differences. Blood pressures were well matched throughout the course of the LIFE trial. This is very persuasive evidence for a specific ARB action. There were similar benefits with regard to cardiovascular death.
Why could that be? As you get hypertension and left ventricular hypertrophy you get left atrial dilatation, and the more your atria dilate the more you are likely to develop AF. The left atrium is somewhat smaller in patients on losartan (data not shown) and the left atrial pressure is slightly lower. This is probably what makes them less prone to developing atrial fibrillation and is another quite important finding.
What about ACE inhibitors? There are some good data for heart failure, not really for hypertension.
In the TRACE study, trandolapril at a standard dose showed a very substantial benefit in patients with established chronic heart failure. You see a very large reduction in new AF in these heart failure patients with trandolapril. You cannot compare LIFE and heart failure because they are completely different groups of patients, but at least there is evidence that both groups of drugs have effects that are beneficial on atrial fibrillation.
To summarise, hypertension and atrial fibrillation is an extreme risk group -approaching 50% event rates. We have very good data for losartan and for people with heart failure we have good data for trandolapril and some other ACE inhibitors, and also for candesartan.
What about people who have LV dysfunction following myocardial infarction? This is the area where there is the most data. Would an ARB be as good as an ACE-I? This was addressed in VALIANT, which was a large trial with 14,700 patients randomised to captopril, valsartan or the combination. 4 These patients had LV dysfunction post recent MI, but not overt heart failure, as the entrance criterion for the study.
Looking at the mortality the results were identical for captopril and valsartan -reassuring, convincing evidence that ARB was as good as an ACE inhibitor, which was the defined therapy at the time. The drugs together had no additional benefit.
For the combination endpoints, valsartan had exactly the same results as captopril and the combination showed no additional benefit. There was an excess of adverse side-effects with the combination, including hyperkalaemia. That tells us that, at least for this very large and wellconducted study, these drugs are equivalent.
Figure 4
Losartan-based regimen resulted in 42% risk reduction in the primary composite endpoint* in patients with a history of AF at baseline. 
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Faced with MI complicated with heart failure, valsartan in the trial was as effective as a large dose of captopril and combining them had no further benefit. The implications in these patients were that valsartan is a clinically effective alternative to ACE inhibitors. For patients with LV dysfunction post-MI it would seem that ACEs are equal to ARBs.
Myocardial infarction
Let me first mention the risks of myocardial infarction. There was a disturbing paper in the BMJ towards the end of last year by Verma and Strauss entitled 'Angiotensin receptor blockers and myocardial infarction'. 5 They claimed in their editorial that ARBs do not reduce or may even increase myocardial infarction compared with ACE inhibitors and some other drugs. They based this on VALUE. They took some data from CHARM, which they coded incorrectly, some from RENAAL, again which they coded incorrectly, and they ignored the two very large trials which addressed the point that they were trying to make. They omitted VALIANT, which I have shown you. They also omitted OPTIMAAL, which was another post-MI trial randomising patients to losartan or to an ACE inhibitor. They also omitted the rest of the CHARM data.
I want to show you all the bits that they left out. In OPTIMAAL and VALIANT there were more than twice as many MIs as in all the trials that Verma and Strauss cited put together. Yet they chose to ignore the two trials that in fact directly addressed ACE versus ARB. This is OPTIMAAL, which did not really achieve its primary endpoint; it looks at reinfarctions with losartan at the rather modest dose of 50mg compared with captopril at a fairly decent dose. The number of new infarctions in these patients who had stable coronary heart disease post-MI was the same with either drug in a sizeable study of 5,477 patients ( Figure 5 ).
The data from VALIANT on cardiovascular death shows no difference between the two. When you add myocardial infarction again there is no difference, but the bars move slightly towards the valsartan side. There are certainly no indications that there is any tendency for excess MIs in the valsartan group: if anything, the results are slightly favourable but not significant. What about ARBs? Figure 6 is CHARM alternative 6 -patients who were intolerant of ACE inhibitors and were randomised to candesartan or placebo. They had established heart failure with impaired LV systolic function. The benefits of candesartan were pretty much the same -about 20% overall benefit -as we have seen with ACE inhibitors. 
R O H I B I T E D
So this is a more or less equivalent finding for a similar number of patients. That gives us comfortable evidence that the drugs are as good as ACE inhibitors.
Adding candesartan to patients who are on an ACE inhibitor is associated with a 15% relative risk reduction in further events -significant and quite encouraging, although not a very large difference overall. It works better with a beta-blocker and better with a target dose of ACE inhibitor. That is important in terms of additional therapy for patients who have established heart failure.
What about ARBs and CHF and patients with systolic dysfunction? They are a good alternative to ACE inhibitors in symptomatic patients intolerant of ACE inhibitors. There is similar efficacy in heart failure, and follwing myocardial infarction with signs of heart failure, ARBs have similar efficacy to ACE inhibitors.
What about combination of ACE and ARB? The ESC say they can be considered in combination with ACE inhibitors. There is a reduction in hospital admissions from CHARM Added and from the Valsartan Heart Failure study (VALHEFT).
In conclusion, in patients with stable coronary heart disease there is a lot more evidence for ACE inhibitors than for ARBs at the moment. Atrial fibrillation, is an exciting area -if you have hypertension the evidence is very substantially in favour of ARBs based on the losartan data. If you have heart failure they are probably roughly equivalent. Post-myocardial infarction ACE-Is are as good as ARBs and combining them in a post-MI group has not been shown to give any additional benefit. In a patient with established heart failure the drugs are comparable and the addition is possibly of some benefit. Thank you.
Questions from the floor
Chair: Adrian, thank you very much indeed for that superb review of four different areas within cardiology. Questions from the floor?
Question: What happened in VALIANT to the blood pressure differences? Were they about the same? It is frightening how superimposed they were in terms of endpoints.
Brady: The blood pressures were very similar, in fact, in VALIANT. I cannot quote the exact figures. The patients were not hypertensive at the start. The majority had pretty well-controlled blood pressures and so any differences would be less than in a hypertension trial for blood pressure reduction. As far as I recall, the blood pressures were almost exactly the same.
Question: And even when you added them in together?
Brady: There was some more hypotension but, as I recall, in the overall blood pressures there was only a very small difference.
McInnes: I just want to point out that these were not full doses of captopril and valsartan that were added in the combination; it was half doses, so it is difficult to look at additive blood pressure.
Brown: Adrian, I enjoyed that. The question you raised at the start about whether in the recent trials there were differences among ACE inhibitors because of the results of PEACE, HOPE etc. -when I read those trial results I felt that the problem in comparing them is that, as you said, there were differences in risk levels in the trials and there were differences in whether they achieved the maximum dose of the ACE inhibitor and therefore in particular there were differences in how much blood pressure-lowering was achieved. I did not feel that you could conclude from those that they were convincing evidence that some ACE inhibitors were better than others.
Brady: That is a debate that will go on from those trials. The investigators from the different trials, as I am sure you have heard, have differences of opinion at cardiology meetings over whether their studies are comparable or whether the drugs themselves are different. Particularly with regard to the PEACE trial with trandolapril, which was given in a rather modest dose in a group of patients who were really already very well treated, where there was also a lot of open label ACE inhibitor used. It is hard to make anything from that trial other than that the dose of added trandolapril did not do very much. It was a more recent trial than the HOPE trial and there was a lot more total care, the blood pressure treatment was better as well. It is just a way of saying: what drugs can you say you have evidence for? You can say that you have evidence for ramipril and for perindopril, but it is not so convincing for trandolapril and quinapril. However, the heart failure data for trandolapril is very persuasive and so it ought to have worked.
Brown: A slightly follow-on question -in your first group of stable coronary heart disease patients who are relatively low risk, the evidence for using an ACE may be marginal, if you take the PEACE result as negative, but in particular there is no evidence that I know of for ARBs. Would it not be better just to say ACE -full stop?
Brady: Absolutely. There is no trial whatsoever of ARBs, so for whatever we are going to be doing for CHD patients, the data support ACEs over ARBs.
Brown:
Putting the evidence aside -because we do not want to be blinkered by the facts -is there any belief that ACEs would be better than ARBs in that setting? Any reason for them to be better in that setting? Just that the trials with ARBs have not been done. I believe they probably would be the same, but at the moment the evidence we have is very substantially in favour of ACE inhibitors. It is a decision whether they are going to put everybody on ACE inhibitors who have stable coronary heart disease. There is FDA approval and European approval for that. The blood pressure-lowering effects are very marginal: in EUROPA, blood pressure was 5/2 during the course of the trial with perindopril 8 mg. So it is not all blood pressure; there is some benefit of ACE inhibition from that study. The contrast with that is the ACTION trial with Adalat LA, which also reduces blood pressure 5/2 mmHg in an identical population group and showed no difference in cardiovascular outcomes other than its symptoms, whereas there is a big difference with ACE inhibitors. So there probably is additional benefit over and above blood pressure-lowering with ACE inhibition.
Chair: That has been an issue of the Joint British
Guidelines about whether the recommendation should be to put these people on ACE inhibitors, and the other argument is that it is all just the blood pressure. That will rage.
Brown: If you compare the same outcomes between ACTION and EUROPA the drugs are similarly effective. As you know, I feel everything is blood pressure and I did not feel that these trials added up to convincing evidence of more than blood pressure reduction.
Brady: My interpretation of ACTION was that the benefits were mostly in TIA and that there was not a benefit in cardiovascular mortality or newonset myocardial infarction. Of course, they are usually using an anti-anginal drug, so you would expect an improvement in revascularisation. I have been asked to talk about these drugs in relation to hypertension and stroke. I hope you will agree with me that if we look at what I consider to be the important properties of an antihypertensive agent, those properties are satisfied by both ACE inhibitors and by angiotensin receptor blockers.
Both reduce blood pressure, they are pretty easy to take -generally once a day; some might argue that some of the drugs should be twice a day, but they are still pretty convenient. Both classes are quite well tolerated: ARBs, as we have heard, probably have the edge because they do not cause cough. We believe they are safe: safety is always a very difficult thing to be sure about, but I see no evidence that these agents are not safe so far, except in pregnancy. The issue I want to address is whether they provide benefits beyond blood pressure reduction in stroke prevention. I am going to start from the position that we do not know and look at the evidence. Again, there is very little evidence from direct comparisons but by looking at what evidence we have for each class of drugs, we may be able to come to some at least preliminary conclusions.
A little bit about stroke first of all. As most of you know, there is a very widely used picture in stroke circles showing Churchill, Roosevelt and Stalin at the Yalta conference in 1945, because each of these great men died from a stroke. The man in the middle was Franklin Roosevelt and the day this photograph was taken he had malignant hypertension. He had a systolic blood pressure of 260 mmHg, and he died a few weeks later from a fatal stroke. On the day of his death allegedly his systolic blood pressure was 300 mmHg. So the most powerful man in the world died from a stroke just 60 years ago in 1945. Some people in this audience may well have been born when he died, so in quite a short lifetime by modern standards we have gone from having absolutely no antihypertensive agents of any value at all -to a state where we have numerous drugs and can agonise over which one is better than another. But at least we do have drugs to reduce blood pressure and prevent these things happening.
We have made enormous advances in clinical pharmacology over the last two or three decades.
The next one to die was Joseph Stalin, who supposedly died of a stroke in 1953. There is, of course, a conspiracy theory that he was murdered but most people believe that he died of a stroke. Then the one who adopted Graham MacGregor's life style intervention to most effect was Sir Winston Churchill. He was very keen on lifestyle, he smoked as much as possible and drank as much as possible, and in this small clinical trial of three he won quite easily because he lived until 1965. That shows you how important lifestyle modification can be! He died also of a stroke. Is the death of great men the reason why we are interested in preventing stroke? Is this why there is an issue of whether ACE inhibitors are different from angiotensin receptor blockers in this respect? Of course not. The reason is that stroke does not kill people. The case of fatality from stroke is low and the problem is that most people survive but they survive in a variable degree of disability, which is hugely disturbing, unpleasant and extremely expensive.
Today stroke probably accounts for about 5% of NHS expenditure, one in eight deaths, as the thirdmost common cause of death, and for comparison we have the figures below for coronary heart disease. So stroke is half as fatal, if you like, as coronary heart disease but it is twice as expensive. We would do well to focus more attention on stroke than we do at the moment on coronary heart disease -which has all but disappeared from this country. I read in a newspaper last year that in England and Wales by the year 2015 no one under the age of 65 will die of a heart attack. So heart attacks are finished, Brady will be out of a job very shortly, and we should be focusing our attention on stroke prevention. That is what I am going to do with you today.
We are going to look briefly at my own unit in Glasgow. We have an acute stroke unit and I thought it might be nice a couple of years ago just to look at the patients who were in one Sunday when I was making up a talk to see what they tell us about stroke. We had 11 beds at that time -we have expanded now and we have 14 beds and will soon have 17. They tend to be older people, roughly even gender mix, but usually slightly more women than men; nearly all infarcts -85% of strokes in Britain are infarcts; very few are haemorrhages. Prognosis -not good for most of these people; variable degrees of disability, very few of them going home self-caring. But the real message is that most of these people had hypertension.
When something happens inside your cranium your blood pressure goes up and about 80% or more of stroke patients will be hypertensive on admission. But within a few hours often, certainly within a day or two, they have normalised. What I mean is a person who had hypertension that was either completely untreated or inadequately treated prior to admission. Nearly all patients with stroke have hypertension. Kennedy showed that in his analysis, and the outcome in these people is much worse than if they have their blood pressure controlled prior to the event.
So it is an important issue -control of blood pressure in stroke. And we know that of all the risk factors for stroke by far and away the most easily treatable is hypertension. You know these figures. This comes from the meta-analysis that you have heard about many times before. A modest reduction in blood pressure, really a rather pathetic reduction -about 10/5 mmHg -will reduce stroke events by about 40%. So high gains are to be had from reducing blood pressure. 1 Trials which have tried to get more rigorous control of blood pressure compared with more usual control, they show that, particularly for stroke, you get added benefits from tight blood pressure control -a 23% further reduction in blood pressure by a small additional reduction in blood pressure. Of all the endpoints stroke appears to be the one that is most clearly related to tight blood pressure control -apart from renal impairment, which Bryan has already talked about. So there is good evidence that tight blood pressure control is important.
Looking at drug therapy, Figure 1 should also be very familiar to you -the Blood Pressure Lowering Trialists meta-analysis. 2 The results of the trials cluster around the regression line which relates blood pressure changes to the effects that we see with the different drugs. We can agonise over whether or not one drug is better than another in stroke prevention, but clearly the main driving force is blood pressure reduction. It may be that calcium channels are a bit better, it may be that ACE inhibitors are a bit worse, but they are all pretty close to this line of identity. In terms of stroke prevention, we see that, certainly compared with placebo, ACE inhibitors are effective and reduce stroke by about 28% (Figure 2 ). But in five comparisons with diuretics and beta-blockers with not much difference in blood pressure between the arms, there is a non-significant tendency for the ACE-Is to do badly. If we look at calcium antagonists against ACE inhibitors, we see the same thing. So it looks as though ACE inhibitors do not do awfully much in terms of stroke prevention. They do reduce stroke because of their blood pressure lowering effects but when you compare ACE-Is with other drugs all the evidence suggests that these drugs do rather badly in comparison.
ARBs, on the other hand, have some quite positive results as far as primary stroke prevention is concerned. Again, the LIFE study provides the best evidence. 3 In that study ARB-based therapy reduced stroke by about 25% compared with a thiazide and beta-blocker combination. This was achieved without much difference in blood pressure between the arms.
It does appear that, independent of blood pressure, ARBs achieve a bit more in the primary prevention of stroke compared with other forms of therapy.
That is confirmed in the Trialists meta-analysis of the looking at ARBs in comparison with other antihypertensive agents ( Figure 3 ).
But it is not all plain sailing for the ARBs. In the VALUE study there was no clear advantage of ARB-based therapy compared with therapy based on amlodipine in terms of stroke outcome. 4 In fact there was a non-significant trend in favour of amlodipine. So the valsartan-treated patients in VALUE in terms of stroke prevention did not seem to do any better than other patients treated in another way, this time with calcium channel-based therapy. Of course, in this trial there was a big difference in blood pressure: the blood pressure advantage was clearly with amlodipine. Early on there were big differences in blood pressure and it was during that time that the main disadvantage for valsartan was seen as far as strokes were concerned.
So the picture for primary prevention of stroke is not too good for ACE inhibitors but promising for ARBs. What about secondary prevention? Stroke has a low case fatality but strokes beget strokes: people who have had strokes are at very high risk of having further strokes -8% within one year, 17% will have a further stroke within five years.
Clearly a number of strategies are appropriate: anti-thrombotic therapy, usually anti-platelet drugs, sometimes warfarin in patients with atrial fibrillation. Statins are clearly appropriate in these people who have had a stroke. What about antihypertensive therapy? For a long time we were very cautious about altering blood pressure in people after a stroke because of worries about perfusion pressure and it is only relatively recently that we have started to see good evidence of what we should be doing following stroke.
The most influential study in this respect was the PROGRESS study. 5 Patients with a prior stroke were randomised to therapy with an ACE inhibitor, perindopril, plus or minus the diuretic indapamide, well after the acute phase when it was felt that the haemodynamics had stabilised. Randomisation was at least two weeks post- 
Figure 2
Meta-analysis of antihypertensive treatment trials: Effects on stroke. stroke. In fact, the average time after a stroke to randomisation into the PROGRESS study was one year, so well after the stroke event. They were given perindopril and it was dependent on the investigator whether they the patients also received the diuretic indapamide. You can see in the whole study a most impressive effect -clear evidence that reducing blood pressure beyond the acute phase of stroke prevents further strokes -a highly significant 28% risk reduction.
If we start dissecting the PROGRESS study and look at the different parts a very interesting pattern starts to appear. Overall in PROGRESS there was a reduction of 9/4 mmHg in blood pressure and a 28% reduction in stroke. For those people who received both drugs it was 12/5 mmHg and 43%. For those who had perindopril alone it was 5/3 mmHg and just 5%. The effect of the combination was exactly that expected from the difference in blood pressure but the effect of perindopril monotherapy was significantly less than expected. This provides some evidence that in secondary prevention too ACE inhibitors are underperforming.
Meanwhile data are accumulating with angiotensin receptor blockers. The MOSES trial was similar to PROGRESS in its design, and included a similar group of patients. Again, average time after the stroke to randomisation was one year. 6 Randomisation to either eprosartanbased therapy or nitrendipine-based therapy -a long-acting calcium channel blocker that was used in the Syst-Eur study. Despite identical control of blood pressure confirmed by 24-hour blood pressure monitoring, there was a highly significant advantage for eprosartan compared with nitrendipine. The only flaw in this study is that it did not use time to first event but used accumulation of all events, very similar in approach to the second Australian National Blood Pressure study. In ACCESS patients were given candesartan 24-72 hours following acute stroke, 7 whether or not they had high blood pressure. The findings suggest that candesartan-treated individuals do better than people not given an ARB immediately after stroke. However, the endpoint is a strange one, a combination of hard endpoints and neurological deficit. Further work is needed. So there you have it. That is the extent of the evidence. Conclusions are difficult because there are no direct comparisons. Both classes of drugs are clearly very useful antihypertensive agents and we already use them very widely, which is appropriate. In the primary and secondary prevention of stroke, however, it does seem that ACE inhibitors underperform and that ARBs do better than you might expect for blood pressure reduction. We need direct comparisons and I believe that ON TARGET and TRANSCEND will provide useful information on primary prevention but my guess is that blood pressure differences will be difficult to explain away.
Perhaps angiotensin II is good for the brain, as Morris Brown suggested many years ago. Non-AT 1receptors in the cerebrovascular circulation may mediate beneficial effects. But this is speculation.
Questions from the Floor
Chair: Thank you very much. So ACEs underperforming for the blood pressure reduction they produce?
McInnes: I believe so. You have seen the evidence. It looks to me as though the ACEs do not do terribly well and maybe the ARBs do a bit better than you would expect.
Chair: I will take small issue with that. In the PROGRESS study you said quite fairly that the clinicians were allowed to add on further diuretic treatment or not. It is a self-selected population because they treated right down to quite low blood pressures -110/70. Therefore they were very well controlled hypertensives and that 5/2 mmHg would be treatment of somebody with already quite low blood pressure where they were loath to add something on. So it would minimise effect and it would also McInnes: I need to give you a wee clinical trials lesson. The relationship between blood pressure and risk is log linear, we believe, and a log linear relationship means that a given reduction in blood pressure at the top end or at the bottom end will have the same proportional effect on risk. So the same proportional effect would be expected by a reduction of 5/2 in a normotensive individual or in a very hypertensive individual. You cannot wriggle out of it that way. But you can wriggle out of it to some extent on the basis that this is not a randomised comparison of perindopril or perindopril plus indapamide.
Chair:
The other side of that coin is that indapamide seemed to do extremely well for protection.
McInnes: It did. Unfortunately, all the data is mixed mostly with indapamide so you cannot tell how other drugs would do. I am a great believer in diuretics.
Jackson: Can you remind us what the results of ASCOT were in relation to stroke? It had an ACE inhibitor in it.
McInnes: I did not include ASCOT in this because I knew that this audience would have been supersaturated by ASCOT on Monday and I thought they would have come to their own conclusions about it. To my mind ASCOT showed that contemporary drugs are better than conventional drugs in reducing stroke. But the problem is that they are also better at controlling blood pressure, so whether or not it is because blood pressure is better, I don't know -just as I do not know the answer to the VALUE conundrum. But certainly contemporary drugs -remember, based on a calcium channel blocker plus an ACE inhibitor, and remember that it has been suggested that ACE inhibitors do a bit better than others for coronary protection, whereas CCBs do a bit better than others for stroke prevention, and that if you combine the two you might get the best of both worlds. So it may have been amlodipine that protected against stroke. I do not know the answer to that.
Sever: Not nitrendipine?
McInnes: That is interesting. Maybe if an ARB had been there it would have been even better.
Chair: The stroke protection in ASCOT was apparent within the first three months, interestingly. The hazard ratio was identical at three months to what it was at the end of the trial.
McInnes: When there were big blood pressure differences.
Chair: Absolutely. But no ACE inhibitor involved.
McInnes: That would be my interpretation, that it is likely to be the amlodipine that was driving the stroke prevention. But we don't know.
Brown: Thanks for your nice words, Gordon, probably the last that I am going to hear for a while. It is worth reminding the younger people that the reason for suggesting that there may be a beneficial effect of angiotensin -your last point -was the original MRC trial. Although it was a post-hoc analysis it looked as though for any given blood pressure level the thiazides were more effective than the beta-blocker at preventing stroke, and since thiazides, if anything, put renin up and beta-blockers put them down, the suggestion was that angiotensin may be protective.
McInnes: I assumed this audience of learned people would know what I was talking about.
Basically that is correct. The drugs which have been unequivocally shown to do rather well in stroke prevention are drugs which tend to increase Angiotensin II -thiazide diuretics, calcium channel blockers and now ARBs. Drugs which reduce angiotensin -beta-blockers and ACE inhibitors -have a rather less impressive portfolio in stroke prevention. Maybe after all you were right, Morris.
Chair: Gordon, thank you very much indeed, and I would like to thank the other three speakers, Adrian, Bryan and Alun, for their superb reviews. 
